DBV Technologies Stock Rises to €3.43 Despite Lowered Price Target
The stock of the French biotech company increased by 2.2% to €3.43 mid-session in a rising Parisian market. The previous day, Kempen maintained its buy recommendation while reducing its price target from €11 to €9. This movement occurred a few days after the publication of the first quarter 2026 results.
Kempen Lowers Target to €9 While Maintaining Buy
Kempen adjusted its opinion on DBV Technologies on May 4. The Dutch firm continues to recommend buying but has lowered its target from €11 to €9. Based on the current price of €3.43, the implied upside potential remains over 160%. This revision follows the quarterly publication on April 30, which reported a net loss of $47.6 million and a significant increase in R&D expenses. The biotech also confirmed two regulatory filings in 2026 for its Viaskin Peanut patch for age groups 4-7 years and 1-3 years. The financial calendar includes the mixed general meeting on June 3, 2026, followed by the half-year results on July 29.
Price Stuck Between Support at €3.34 and MM50 at €3.60
The stock is trading in a narrow range. The price at €3.43 is just above the support at €3.34, already tested at the beginning of the month, and remains below the 50-day moving average at €3.60. The 200-day moving average at €2.79, however, confirms the underlying bullish trend, with a performance of 125.5% over the year. The RSI at 43 remains neutral and does not indicate either overselling or overbuying. Today's rebound is in the lower part of the Bollinger Bands (lower boundary at €3.30), without breaching any major technical level. The next concrete appointment is the general meeting on June 3, 2026, before the half-year results on July 29.
